NCIC CTG BR.26: A phase III randomized, double blind, placebo controlled trial of dacomitinib versus placebo in patients with advanced/metastatic non-small cell lung cancer (NSCLC) who received prior chemotherapy and an EGFR TKI. Conference Paper uri icon

  •  
  • Overview
  •  
  • Research
  •  
  • Identity
  •  
  • Additional Document Info
  •  
  • View All
  •  

authors

  • Ellis, Peter
  • Liu, Geoffrey
  • Millward, Michael
  • Perrone, Francesco
  • Shepherd, Frances A
  • Sun, Sophie
  • Cho, Byoung Chul
  • Morabito, Alessandro
  • Stockler, Martin R
  • Wierzbicki, Rafal
  • Cohen, Victor
  • Blais, Normand
  • Sangha, Randeep S
  • Favaretto, Adolfo G
  • Kang, Jin Hyoung
  • Wilson, Carolyn F
  • O'Connell, Joseph
  • Ding, Keyue
  • Goss, Glenwood D
  • Bradbury, Penelope Ann

publication date

  • May 20, 2014